“ Public perception about clinical trials has witnessed a drastic change ”
In an exclusive interview , Ajay Tandon , Managing Director , Veeda Clinical Research Limited shared his views on a host of issues including the India ’ s clinical research industry , his company ’ s current operations and outlook .
BY RAHUL KOUL
Ajay Tandon has been associated with Veeda for over two years . He holds a bachelor ’ s degree in engineering ( electrical ) from the University of Delhi and a post graduate diploma in management from the Indian Institute of Management , Ahmedabad . He has experience in investment advisory and previously has been associated with CX Advisors LLP , Citi Bank , India and TRG Advisors India Private Limited .
What are the key milestones achieved by Veeda Clinical Research in the last few years ?
Veeda offers a comprehensive portfolio of clinical , preclinical and bio-analytical services to support innovator , biosimilar and generic drug development programs of our global clientele including pharma , biopharma , agrochemicals , industrial chemicals , herbal , nutraceuticals , and medical devices .
A few of the milestones achieved by the company are establishment of Ingenuity Biosciences Private Limited , a 50:50 joint venture collaboration with Canadabased Somru BioScience Inc ., to enhance its capabilities in biosimilars . Veeda also added pre-clinical research services to the portfolio by acquiring Bangalore-based CRO , Bioneeds India . We also successfully commissioned a fully equipped 18-bedded clinic for conduct of phase 1 clinical studies at Ahmedabad ,. It focuses on conduct of studies which include first-in-human single ascending dose studies and multiple ascending dose studies ,
08
BioVoiceNews | October 2022